Aarti Drugs Ltd (BOM:524348)
₹ 511.3 18.4 (3.73%) Market Cap: 47.01 Bil Enterprise Value: 52.44 Bil PE Ratio: 25.90 PB Ratio: 3.46 GF Score: 92/100

Q2 2023 Aarti Drugs Ltd Earnings Call Transcript

Oct 21, 2022 / 06:30AM GMT
Release Date Price: ₹461.35 (+0.07%)
Operator

Ladies and gentlemen, good day, and welcome to Aarti Drugs Limited Q2 FY23 earnings conference call. This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions and expectation of the company as on date of this call. These statements are not the guarantees of future performance and involve risk and uncertainties that are difficult to predict. (Operator Instructions). Please note that this conference is being recorded.

I now hand the conference over to Mr. Adhish Patil, CFO at Aarti Drugs Limited. Thank you, and over to you, sir.

Adhish Patil
Aarti Drugs Ltd. - CFO

Thank you very much. Good afternoon, everyone. On behalf of Aarti Drugs Limited, I extend a very warm welcome to everyone joining us today to discuss our financial results for the quarter ended September 30, 2022. On this call, we are joined by Mr. Harshit Savla, Joint Managing Director; Mr. Harit Shah, Whole-Time Director of Aarti Drugs; and Mr. Vishwa Savla, Managing Director of Pinnacle Life Science Private Limited; and SGA, our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot